RecruitingPhase 1NCT07290036

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Studying NON RARE IN EUROPE: Psoriatic arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UCB Biopharma SRL
Principal Investigator
UCB Cares
001 844 599 22733 (UCB)
Intervention
Bimekizumab regimen 1 iv(drug)
Enrollment
392 target
Eligibility
18 years · All sexes
Timeline
20252028

Study locations (20)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07290036 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Psoriatic arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Psoriatic arthritis

← Back to all trials